Synthesis, Structure and Biological Activity of Novel 4,5-dihydro-1H-imidazol-2-yl-phthalazine Derivatives and Their Copper(II) Complexes

þÿ B a l e w s k i , A u k a s z

Multidisciplinary Digital Publishing Institute
2022-11-01

þÿ B a l e w s k i , A . ; K o k o s z k a , J . ; F e d o r o w i c z , J . ; I l i n a , P . ; T a m m e l a , P . ; G d
Synthesis, Structure and Biological Activity of Novel
4,5-dihydro-1H-imidazol-2-yl-phthalazine Derivatives and Their Copper(II) Complexes. Med.
Sci. Forum 2022, 14, 58.

http://hdl.handle.net/10138/352644

medical sciences forum

MDPI

Abstract

Synthesis, Structure and Biological Activity of Novel 4,5-dihydro-1*H*-imidazol-2-yl-phthalazine Derivatives and Their Copper(II) Complexes †

Łukasz Balewski [1,*], Jakub Kokoszka [1], Joanna Fedorowicz [1], Polina Ilina [2], Päivi Tammela [2], Maria Gdaniec [3] and Anita Kornicka [1]

[1] Department of Chemical Technology of Drugs, Medical University of Gdańsk, 80-416 Gdansk, Poland
[2] Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, 00014 Helsinki, Finland
[3] Faculty of Chemistry, A. Mickiewicz University, 61-712 Poznań, Poland
* Correspondence: lukasz.balewski@gumed.edu.pl
† Presented at the 8th International Electronic Conference on Medicinal Chemistry, 1–30 November 2022; Available online: https://ecmc2022.sciforum.net/.

Abstract: As a continuation of our previous investigations aimed at the synthesis of novel nitrogen-containing heterocycles and their metal complexes, we have now prepared two series of compounds incorporating a phthalazine ring at the position C_2 of 4,5-dihydro-1*H*-imidazole. The starting phthalazine (**I**) in the reaction with 2-chloroimidazoline (**II**) gives rise to the formation of pseudobase **III**. Then, compound **III** upon treatment with HOSA yields betaine which under basic conditions gives 2-(4,5-dihydro-1*H*-imidazol-2-yl)phthalazin-1(2*H*)-imine (**IV**). In turn, the reactions of compound **IV** with a variety of acyl and sulfonyl chlorides lead to the formation of benzamides (**V**) and benzenesulfonamides (**VI**). Moreover, compounds **V** and **VI** can be transformed into corresponding 2-(4,5-dihydro-1*H*-imidazol-2-yl)phthalazin-1(2*H*)-one derivatives **VII** and **VIII**. Such ligands are susceptible to the reaction with $CuCl_2$ giving rise to the formation of corresponding copper(II) complexes: dichloro[2-(4,5-dihydro-1*H*-imidazol-2-yl)phthalazin-1(2*H*)-imine]copper(II) (**1**), dichloro[2-(1-benzoyl-4,5-dihydro-1*H*-imidazol-2-yl)phthalazin-1(2*H*)-one]copper(II) (**2**) and dichloro{bis-[2-(1-(phenylsulfonyl)-4,5-dihydro-1*H*-imidazol-2-yl)phthalazin-1(2*H*)-one]}copper(II) (**3**). The most promising results of biological studies were obtained for complex **1** towards the HeLa cell line (IC_{50} = 2.13 μM) without a toxic effect against fibroblasts BALB/3T3 (IC_{50} = 135.30 μM), which pointed towards its selectivity as a potential antitumor agent. It should be pointed out, that corresponding free ligand 2-(4,5-dihydro-1*H*-imidazol-2-yl)phthalazin-1(2*H*)-imine (**IV**) was less active than its metal complex (IC_{50} = 87.74 μM).

Keywords: phthalazine; imidazoline; copper(II) complexes; synthesis; structure; X-ray; cytotoxic activity

Citation: Balewski, Ł.; Kokoszka, J.; Fedorowicz, J.; Ilina, P.; Tammela, P.; Gdaniec, M.; Kornicka, A. Synthesis, Structure and Biological Activity of Novel 4,5-dihydro-1*H*-imidazol-2-yl-phthalazine Derivatives and Their Copper(II) Complexes. *Med. Sci. Forum* **2022**, *14*, 58. https://doi.org/10.3390/ECMC2022-13272

Academic Editor: Alfredo Berzal-Herranz

Published: 1 November 2022

Supplementary Materials: The poster can be downloaded at: https://www.mdpi.com/article/10.3390/ECMC2022-13272/s1.

Author Contributions: Conceptualization, Ł.B. and A.K.; methodology, Ł.B., J.F., J.K.; formal analysis, Ł.B., M.G.; investigation, Ł.B., A.K., M.G., J.F.; data curation, Ł.B.; writing—original draft preparation, Ł.B.; writing—review and editing, Ł.B. and A.K.; visualization, Ł.B.; supervision, A.K., P.I. and P.T.; project administration, Ł.B. and A.K.; funding acquisition, A.K. All authors have read and agreed to the published version of the manuscript.

Funding: This research was supported by the Funds for Statutory Activity of the Medical University of Gdańsk (ST-020038/07).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.